Figure 1

Survival analysis of NSCLC comparing patients with PBRM1 mutations and PBRM1 wild type. (A) Survival analysis of OS in patients with ICB-treated NSCLC. (B) Survival analysis of PFS in patients with ICB-treated NSCLC. (C) Survival analysis of OS in patients with NSCLC from the TCGA cohort. (D) Survival analysis of PFS in patients with NSCLC from the TCGA cohort.